Related Experiment Video
Updated: Sep 5, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Bradycardia From a Non-selective Beta-Adrenergic Antagonist, Timolol, Applied Ophthalmologically for Glaucoma
Gedaliah May1, Daniel Miller2, Daniel Fuchs1
1Internal Medicine, Coney Island Hospital, Brooklyn, USA.
Abstract:
Non-selective beta-adrenergic antagonists are used systemically to treat hypertension and tachycardia and are used ophthalmologically for glaucoma. Generally, ophthalmological medications don't have systemic effects, as they are applied specifically to a local area. In this case, however, it appears that timolol, a beta-blocker, had systemic effects on heart rate. This is something that prescribing physicians must be wary of when evaluating patients with glaucoma who have cardiovascular comorbidities. Additionally, patients should be informed of the importance of occluding the puncta when receiving eye treatments to lessen the risk of systemic effects.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: β-Blockers

